Bayer Aktiengesellschaft (BAYZF)
OTCMKTS
· Delayed Price · Currency is USD
38.70
-1.09 (-2.74%)
At close: Dec 5, 2025
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
0.71
Revenue / Employee
499.28K EUR
Employees
91,864
Market Cap
38.06B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Zomedica | 29.45M |
Bayer Aktiengesellschaft News
- 2 days ago - Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome - Business Wire
- 2 days ago - RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints - Business Wire
- 2 days ago - Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study - GuruFocus
- 2 days ago - Bayer releases data for contrast agent gadoquatrane in children - Seeking Alpha
- 3 days ago - Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit - GuruFocus
- 3 days ago - Bayer Welcomes Solicitor General Support In Supreme Court Review Of Roundup Case - Nasdaq
- 3 days ago - Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today - Investopedia
- 3 days ago - Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire